Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

WuXi Biologics Invests $60 Million in Another New Plant -- In Singapore This Time

publication date: May 22, 2018

WuXi Biologics will spend $60 million to build a biologics CDMO plant in Singapore. The facility will be WuXi Biologics' tenth manufacturing plant globally and the third new facility it has announced in three weeks. Previously, the company released plans to build a $392 million plant in Ireland and then a $240 million facility in the northern China city of Shijiazhuang. During 2011-14, WuXi Biologics opened three large facilities in Shanghai, Wuxi City and Suzhou. When the Singapore plant is up and running, it will provide approximately 150 jobs. More details....

Stock Symbol: (HK: 2269)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.